76.04 -0.83 (-1.08%)
After hours: 6:43PM EDT
|Bid||76.04 x 800|
|Ask||77.50 x 1300|
|Day's Range||74.03 - 77.12|
|52 Week Range||65.25 - 92.64|
|Beta (5Y Monthly)||0.69|
|PE Ratio (TTM)||20.18|
|Earnings Date||Apr 27, 2020|
|Forward Dividend & Yield||2.44 (3.31%)|
|Ex-Dividend Date||Mar 12, 2020|
|1y Target Est||96.56|
Merck Announces KEYTRUDA Significantly Improved Progression-Free Survival as First-Line Treatment for Advanced MSI-H or dMMR Colorectal Cancer
Major drugmakers Merck & Co. Inc.,, Pfizer Inc. and Eli Lilly and Co. are joining together to establish volunteer programs to enable employees who are licensed medical professionals to aid in the fight against COVID-19 while maintaining their base pay.
Medical Professionals Across Merck, Pfizer and Eli Lilly Activate to Support Health Systems, First Responders and Patients Amid COVID-19 Pandemic
RA Capital and Boxer Capital continued a busy financing week, investing undisclosed amounts in a local startup working with cancer giant Merck & Co.
Intercept Pharmaceuticals hoping for approval on medication to compete in large and fast-growing market for NASH treatments Continue reading...
DOW UPDATE The Dow Jones Industrial Average is soaring Monday afternoon with shares of Johnson & Johnson and Merck delivering strong returns for the index. Shares of Johnson & Johnson (JNJ) and Merck (MRK) have contributed to the blue-chip gauge's intraday rally, as the Dow (DJIA) is trading 720 points, or 3.
DOW UPDATE Shares of Johnson & Johnson and Merck are trading higher Monday afternoon, sending the Dow Jones Industrial Average soaring. The Dow (DJIA) was most recently trading 571 points (2.6%) higher, as shares of Johnson & Johnson (JNJ) and Merck (MRK) are contributing to the index's intraday rally.
DOW UPDATE Shares of Microsoft and Johnson & Johnson are posting positive growth Monday afternoon, sending the Dow Jones Industrial Average soaring. The Dow (DJIA) is trading 438 points higher (2.0%), as shares of Microsoft (MSFT) and Johnson & Johnson (JNJ) have contributed to the index's intraday rally.
DOW UPDATE Led by strong returns for shares of Johnson & Johnson and Microsoft, the Dow Jones Industrial Average is soaring Monday afternoon. The Dow (DJIA) is trading 529 points higher (2.4%), as shares of Johnson & Johnson (JNJ) and Microsoft (MSFT) are contributing to the blue-chip gauge's intraday rally.
DOW UPDATE The Dow Jones Industrial Average is rallying Monday morning with shares of Johnson & Johnson and Intel delivering strong returns for the blue-chip average. Shares of Johnson & Johnson (JNJ) and Intel (INTC) are contributing about one third of the index's intraday rally, as the Dow (DJIA) is trading 427 points, or 2.
DOW UPDATE Led by positive growth for shares of Johnson & Johnson and Intel, the Dow Jones Industrial Average is rallying Monday morning. The Dow (DJIA) is trading 328 points, or 1.5%, higher, as shares of Johnson & Johnson (JNJ) and Intel (INTC) are contributing about a third of the blue-chip gauge's intraday rally.
Merck & Co Inc said on Saturday that vericiguat, an investigational drug for patients with worsening chronic heart failure, met the primary efficacy endpoint in the VICTORIA trial. The VICTORIA trial is a Phase 3 study evaluating the efficacy and safety of the drug vericiguat, which is being jointly developed with Bayer AG, the company said. Compared with a placebo, the drug reduced the risk of heart failure hospitalization or cardiovascular death in heart failure patients with reduced ejection fraction (HFrEF) when given in combination with available therapies, Merck said.
Investigational Drug Vericiguat Significantly Reduced the Risk of the Composite Endpoint of Heart Failure Hospitalization or Cardiovascular Death
The vaccine, expected to produce data from a clinical trial in 2022, is designed to essentially carry 24 vaccines in one against pneumonia.
Johnson & Johnson Chief Scientific Officer Dr. Paul Stoffels predicts the most vulnerable will begin to receive vaccines within 12 months to prevent COVID-19.
United Parcel Service (NYSE: UPS) has announced a collaboration with Wingcopter, a German-based electric vertical take-off and landing (VTOL) aircraft startup, to scale up its drone delivery operations in the U.S. and across the world. Wingcopter will be working with UPS Flight Forward (UPSFF), the drone delivery subsidiary of UPS, to create this next generation of package delivery drones. "Drone delivery is not a one-size-fits-all operation. Our collaboration with Wingcopter helps pave the way for us to start drone delivery service in new use-cases. UPS Flight Forward is building a network of technology partners to broaden our unique capability to serve customers and extend our leadership in drone delivery," said Bala Ganesh, vice president of the UPS Advanced Technology Group. The drone delivery segment has gained momentum in recent years, thanks to the ever-growing importance of expedited delivery, especially within the ecommerce market. With delivery speed being considered an important marker of end consumers' satisfaction, logistics companies see the relevance in investing across two distinct unmanned VTOL drone segments – long-range heavy-haul and short-range light-haul aircraft. While heavy-haul drones are typically used to deliver across remote and impoverished regions, light-haul drones are helpful across the last-mile delivery segment, particularly for hastening delivery in urban spaces with frequent traffic deadlock. For UPS, the partnership with Wingcopter will be within the heavy-haul VTOL aircraft segment, following Wingcopter's track record in "delivering a variety of goods over long distances in multiple international settings."The Wingcopter collaboration is UPSFF's first venture with a drone manufacturer. In a statement, UPS has stated that the companies will jointly work to gain regulatory certification for commercial flight of unmanned drones in the U.S., as well as building a diverse fleet of drones with varying capabilities to meet different customer needs. "We are proud to partner with UPS, a global giant in delivery and logistics. Together we aspire to extend the speed and reach of package delivery," said Tom Plümmer, Wingcopter chief executive officer and co-founder. "Our vision has always been to leverage technology to improve the lives of people around the world, and the strategic relationship with UPS will further accelerate our growth and global expansion, strengthening our role as an industry leader in drone technology."Wingcopter comes into this partnership fresh from the successful completion of its first drone delivery trial this February with healthcare giant Merck, delivering a shipment from a Merck & Co., Inc. (NYSE: MRK) lab in Gernsheim, Germany, to the Merck headquarters in Darmstadt, Germany. The test was a beyond the visual line of sight (BVLOS) project, which meant that the drone flew over inhabited regions that included buildings, electric power lines, traffic and people. The drone startup has considerable experience in delivering shipments for BVLOS projects across several domains, including commercial factory-to-factory deliveries, humanitarian programs and medical emergencies. Wingcopter's VTOL aircraft is unique in the market, as its patented tilt-rotor mechanism enables a seamless transition between two drone modes – multicopter for hovering and fixed-wing for low-noise forward flight. These modes help the drone to stabilize itself even when faced with harsh weather conditions, including wind speeds of up to 45 mph. The aircraft can reach speeds up to 150 mph with a range of approximately 75 miles. See more from Benzinga * Courier Giants Help U.S. Operate Pop-Up Virus Test Centers * Vehicle Electrification Is Not Just About Reducing Emissions * Today's Pickup: Amazon Insourcing Hurting DHL Globally(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Technical analysis offers unique insights into market trends, especially in times of chaos. Why three practitioners see support for the S&P 500 around 2300. What the charts say about oil, emerging markets, health care, Walmart.
Pfizer (PFE) is set to jointly develop BioNTech's potential coronavirus vaccine. Regeneron/Sanofi (SNY) and Roche will study their RA drugs, Kevzara & Actemra, respectively to treat severe COVID-19 infection.
While biopharma companies and academic laboratories close up shop, Sensei Biotherapeutics plans to open a research hub in SmartLab’s Seaport facility.